Literature DB >> 3506526

Cyclophosphamide- or ifosfamide-treated L 1210 leukaemia cells: immunogenicity, viability and metabolism.

T Skórski1, M Kawalec, G Hoser.   

Abstract

We have demonstrated that lymphoid leukaemia L 1210 cells treated with cyclophosphamide or ifosfamide were immunogenic for semisyngeneic CD2F1 mice and that they effectively prevented the development of the later inoculated leukaemia L 1210 cells. Non-dividing and immunogenic L 1210 cells were only obtained when an appropriate dose of cyclophosphamide was applied. These cells lost their immunogenicity after killing by repeated freezing and thawing or after fixing with glutaraldehyde. Non-dividing immunogenic L 1210 cells treated with cyclophosphamide possessed the histocompatibility and tumour-associated transplantation antigens and had the ability to synthesize proteins, the RNA and partially the DNA.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3506526

Source DB:  PubMed          Journal:  Folia Biol (Praha)        ISSN: 0015-5500            Impact factor:   0.906


  2 in total

1.  Successful chemoimmunotherapy of murine L1210 lymphatic leukemia with cyclophosphamide and mafosfamide-treated leukemia cells.

Authors:  M Kawalec; T Skórski; J Kawiak
Journal:  Invest New Drugs       Date:  1988-09       Impact factor: 3.850

2.  New application of a stabilized active cyclophosphamide derivative (mafosfamide, ASTA Z 7654)--immunogenic properties of lymphatic leukemia L 1210 cells treated in vitro with the drug.

Authors:  T Skórski; M Kawalec
Journal:  Invest New Drugs       Date:  1987       Impact factor: 3.850

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.